{
  "id": 14225369,
  "title": "BioNTech’s head and neck cancer vaccine misses first of two goals",
  "url": "https://urgent.news/2026/10/13/biontechs-head-and-neck-cancer-vaccine-misses-first-of-two-goals",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-13T14:59:28.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/biontechs-head-and-neck-cancer-vaccine-misses-first-of-two-goals/"
  },
  "original_language": "en",
  "account": null,
  "summary": "An experimental mRNA cancer vaccine from BioNTech failed to meet one of two primary endpoints in a pivotal trial, adding to the obstacles faced by the company’s pipeline for such treatemts. The therapy, known as ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "BioNTech cancer drug misses key trial endpoint",
        "url": "https://urgent.news/2026/10/13/biontech-cancer-drug-misses-key-trial-endpoint",
        "published": "2026-10-13T10:48:33.000Z"
      },
      {
        "outlet": "BioPharma Dive",
        "title": "BioNTech mRNA cancer immunotherapy misses first objective in key study",
        "url": "https://urgent.news/2026/10/13/biontech-mrna-cancer-immunotherapy-misses-first-objective-in-key-study",
        "published": "2026-10-13T16:24:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}